




CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231, on the date below:

July 13, 2004
Date


Debbie Berroth

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Graff, et al.

Serial No.: 10/771,620

Filed: February 4, 2004

For: MARKERS FOR DIAGNOSING
AND TRADE BREAST AND OVARIAN
CANCER

Group Art Unit: 1616

Examiner: Unknown

Atty. Dkt. No: UNI919/4-8US

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the document listed on the attached Form SB/08A be considered by the Examiner and made of record. A copy of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g),(h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be

an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Vinson & Elkins L.L.P. Deposit Account No. 22-0365/UNI919/75002.

Respectfully submitted,


M. Michelle Muller

M. Michelle Muller
Reg. No. 42,913
Attorney for Applicant

Vinson & Elkins L.L.P.
2300 First City Tower
1001 Fannin
Houston, Texas 77002-6760
512/495-8441

Date: July 13, 2004

bcc: Tracey Davies [Firm]
Marya Breig [Firm]

INFORMATION DISCLOSURE STATEMENT BY APPLICANT 		Application Number		10/771,620	
		Filing Date		February 4, 2004	
		First Named Inventor		Graff	
		Group Art Unit		1616	
		Examiner Name		Unknown	
Sheet	1	Attorney Docket Number		UNI919/4-8US	
NON-PATENT LITERATURE DOCUMENTS					
	A	Dorsey, et al., "Immunotherapy with Interleukin-10 Depends on the CXC Chemokines Inducible Protein-10 and Monokine Induced by IFN- γ ," Cancer Research 62, 2606-2610, May 1, 2002.			
	B	Sgadari, et al., "Mig, the Monokine Induced By Interferon- γ , Promotes Tumor Necrosis In Vivo," Blood, Vol. 89, No. 8 (Apr 15, 1997): 2635-2643.			
	C	Addison, et al., "The CXC Chemokine, Monokine Induced by Interferon- γ , Inhibits Non-Small Cell Lung Carcinoma Tumor Growth and Metastasis," Human Gene Therapy 11:247-261 (Jan. 20, 2000).			
	D	Ruehlmann, et al., "MIG (CXCL9) Chemokine Gene Therapy Combines with Antibody-Cytokine Fusion Protein to Suppress Growth and Dissemination of Murine Colon Carcinoma," Cancer Research 61, 8498-8503, Dec. 1, 2001.			
	E	Feinberg, et al., "Transport of dsRNA into Cells by the Transmembrane Protein SID-1," Science, Vol. 301, Sep. 12, 2003.			
	F	Winston, et al., "Systemic RNAi in <i>C. elegans</i> Requires the Putative Transmembrane Protein SID-1," Science, Vol. 295, Mar 29, 2002.			
Examiner Signature				Date Considered	